The Seed Investor sits down with ABcann CEO Aaron Keay to discuss ABcann and what it takes to be the strongest grower in the Marijuana sector.
Marijuana Investing
Recent Competitor Recalls Illustrate Importance of ABcann Global’s (TSX.V: ABCN) (OTCQB: ABCCF) Innovative, Pesticide-Free Cannabis Growth Practices
Ken Clement said in an update published on the ABcann website. “Providing a high quality, standardized pesticide-free product to our patients remains our number one priority as we initiate our largest expansion plans to date.”
INMED PHARMACEUTIC COM NPV (CSE: IN OTCBB: IMLFF) Closes In Green
InMed Pharmaceuticals (CSE: IN OTCBB: IMLFF) is picking up steam, with another recent article in MMJReporter.com
Canopy Growth and New Brunswick Sign Historic Supply MOU
Canopy Growth Corporation (TSX: WEED) and the Province of New Brunswick today announced a significant milestone in the history of Canadian cannabis, entering into an agreement to guarantee a reliable and high-quality supply of cannabis products into New Brunswick's retail stores.
University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral CBD intake, having engineered the product to enhance absorption through the intestinal tract without active compounds being destroyed by stomach acid or broken down by the liver, and this revolutionary product also masks the unpleasant flavor of cannabis compounds.
Cronos (TSX.V MJN) Announces Private Placement of Common Shares
Cronos Group expects to issue up to 4,444,444 common shares at $2.25
Canopy Growth Completes Sale of Non-Core Subsidiary for $7.0 Million and Enters Three Year Product Supply Agreement
Canopy Growth Corporation (TSX:WEED) has completed an agreement with Cannabis Care Canada Inc. to sell its wholly-owned subsidiary Mettrum (Bennett North) Ltd. , which is licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations to produce and sell dried cannabis and cannabis oil.
Eaze Continues Advancing Cannabis Industry with an Additional $27M Raised
Eaze, the leading cannabis technology company, announced today an additional $27 million in Series B financing, led by Bailey Capital with participation from DCM Ventures, Kaya Ventures and FJ Labs.
Innovative Cannabis Players Offer Promising Entry into Explosive Market
Analysts have predicted the cannabis market in the United States could reach $24.1 billion by 2025, and recent polls indicate 61 percent of Americans now believe marijuana use should be federally legalized1.
INMED PHARMACEUTICALS (OTC:IMLFF) Pops on Biosynthesis IP Move
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) is an interesting player in the MMJ space. One of the reasons for that sense is the company’s habit of innovation and focus on intellectual property.
Global Payout, Inc. (GOHE) Subsidiary Enters Letter of Intent with BlazeNow, Inc.
Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that its majority owned subsidiary, MoneyTrac Technology, Inc., has executed a Letter of Intent with BlazeNow, Inc., a majority owned subsidiary of MediaTechnics Corporation (OTC: MEDT).
Canopy Growth (TSX: WEED) Enters Australia through AusCann Group Holdings
Canopy Growth Corporation (TSX:WEED) has entered into a supply agreement with AusCann, whereby Canopy Growth will act as AusCann's exclusive supplier of medical cannabis for the Australian market.
India Globalization Capital, Inc. (NYSE: IGC) Announces Alzheimer’s Drug Candidate Targeting Aβ Proteins
India Globalization Capital, Inc. (NYSE MKT: IGC) launched a press release detailing its work on a drug candidate, IGC-ADI, that targets the buildup of lesions in the brain associated with Alzheimer’s.
ChineseInvestors.com, Inc. (CIIX) Records 76% YOY Increase in Revenues for FY2017
Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its financial results for the fiscal year ended May 31, 2017.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Files Provisional Patent Covering Proprietary Biosynthesis Program
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its filing of a provisional patent application pertaining to the company’s biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.